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ABSTRACT
The co-formulated lopinavir/ritonavir significantly reduces quinine concentration in healthy volunteers due 
to potential drug-drug interactions (DDIs). However, DDIs  information  in malaria and HIV co-infected 
patients are lacking.  The objective of the study was to apply physiologically-based pharmacokinetic 
modeling to predict optimal dosage regimens of quinine when co-administered with lopinavir/ritonavir in 
malaria and HIV co-infected patients with different conditions.  The developed model was validated against 
literature. Model verification was evaluated using the accepted method.  The verified  PBPK models 
successfully predicted unbound quinine disposition when co-administered with lopinavir/ritonavir in co-
infected patients with different conditions. Suitable dose adjustments to counteract with the DDIs have 
identified in patients with various situations, i.e., a 7-day course at 1800 mg TID in malaria patients with A
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HIV infection, 648 mg BID in chronic renal failure, 648 mg TID in hepatic insufficiency except for severe 
hepatic insufficiency (324 mg BID), and 648 mg TID in CYP3A4 polymorphism.   
Keywords: Physiologically-based  pharmacokinetics, malaria, HIV, drug-drug interactions, quinine, 
ritonavir, lopinavir
INTRODUCTION
Malaria is reported as the third frequent cause of HIV-related morbidity in Africa (human 
immunodeficiency virus).1 The estimated number of HIV co-infected with malaria deaths was 65,000 in 
Africa every year.2  The prevalence of malaria coinfection with HIV varies from 0.7 to 47.5% worldwide.2 
Additionally, malaria patients co-infected with HIV are prone to have symptomatic parasitemia and high 
parasitemia.3 Thus, patients are required to receive both antimalarial and antiretroviral drugs. The incidence 
and relevance of drug-drug interactions (DDIs) between the antimalarial drugs (victim) and antiretroviral 
drugs (perpetrators) have been increasing and becoming unavoidable, resulting in impaired efficacy of 
malaria treatment or increase its adverse effects.2,4
Previous two studies of quinine co-administered with ritonavir-boosted lopinavir in healthy 
volunteers showed that a single oral dose of 600 mg quinine co-administered with Lopinavir/ritonavir 
resulted in a significant decrease in quinine concentrations.5,6 A three-fold increase in quinine dosage was 
suggested to counteract with the effects of lopinavir/ritonavir.5 In contrast, a study of quinine co-
administered with ritonavir alone resulted in a four-fold increase in quinine concentrations.7 The induction 
of UDP-glucuronyl transferase (UGT) enzyme by ritonavir and the protein-binding displacement effect of 
lopinavir may be the critical factors that reduce quinine concentrations.5,6 These two studies have 
highlighted a concern when quinine is co-administered with lopinavir/ritonavir for the treatment of HIV 
patients co-infected with malaria.  A
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Renal failure is a common condition in patients with severe malaria, and the incidence varies from 
15% to 48%.8 This organ impairment has been reported to influence quinine plasma concentrations.8 
Dosage reduction in patients with chronic renal failure without dialysis was suggested based on computer-
assisted modeling.9  However, the optimal dose for quinine co-administered with lopinavir/ritonavir in 
patients is still lacking.  Cytochrome P450 3A4/5 (CYP3A4/5) enzyme has been recognized as a significant 
human drug-metabolizing enzyme with high inter-individual variations across different ethnicities.10,11  In 
vitro study demonstrated a reduction of quinine intrinsic clearance in the 23 CYP3A4 variants compared to 
the wild-type CYP3A4*1.12  Clinical relevance of this association remains to be clarified. 
The traditional dosing strategy for dose adjustment is ‘trial and error’ to find the optimal dose 
based on the clinical response. This strategy could result in inappropriate dose regimen and, thus, increase 
the risk of toxicity and/or treatment failure in patients.  Physiologically-based pharmacokinetic (PBPK) 
modeling has been recognized as a reliable tool to predict drug disposition based on the information from 
in vitro and in vivo studies.13 This model is applied to predict optimal dose regimen in various situations, 
e.g., concomitant medication (DDIs), renal insufficiency, genetic polymorphism, hepatic insufficiency, as 
well as multiple diseases including malaria and HIV co-infection.13-15 The objective of this study was to 
apply PBPK modeling to predict optimal dose of quinine when co-administered with lopinavir/ritonavir in 
patients co-infected with malaria and HIV in the following conditions: (i) chronic renal failure, (ii) hepatic 
insufficiency, and (iii) CYP3A4 polymorphism.
METHODS
Model construction
The whole PBPK model was constructed for three drugs combination (quinine, ritonavir, and lopinavir) 
based on the previously published information of ritonavir-boosted darunavir (DRV/r)16 using 
Simbiology® version 5.8.2, a product of MATLAB® version 2019a (MathWorks, Natick, MA, USA). The 
physicochemical and biochemical properties of each drug and human physiological parameters were 
obtained from the published articles.17-30 The essential parameters for model construction, including 
physicochemical, physiological, and biochemical properties of each drug are summarized in Table 1 . 
Initial model assumptions were blood-flow limited model, immediate dissolution, absence of absorption 
from the stomach and large intestine, and absence of enterohepatic recirculation. The fm,cyp3A4 and fm, UGT1A1 
for quinine were assumed to be 0.44 and 0.56, respectively.31 There was no effect of CYP3A4 inhibition 
from 3-hydroxyquinine. The flow charts of single model construction and DDIs model are shown in Figure 
1 and Figure 2, respectively.
Virtual population simulation
Plasma concentrations of unbound quinine, ritonavir, and lopinavir were simulated in 100 virtual 
population aged between 18 and 60 years in the fasting state for malaria and HIV co-infected patients and A
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CYP3A4 polymorphism. The age range of patients used in renal and hepatic insufficiency conditions were 
30-60 years. CYP3A4 variants resulted in the changes in intrinsic metabolism of quinine to 0.226-fold 
(CYP3A4*3: M44T5), 0.058-fold (CYP3A4*13: P416L), 0.176-fold (CYP3A4*18: L293P), and 0.43-fold 
(CYP3A4*19: P467S).12
Model verification
Eight published clinical articles were used for model validation.5-7,9,32-35 The simulated results were 
compared with clinical published data. The details of each simulation are shown in Table 2. AAFEs 
between the predicted and published values were estimated to determine model accuracy. The most 
common accepted AAFEs are within 2-fold.36 The mathematical equation for AAFE is as follow:
AAFE = 10(abs(log(prediction/observation))/n)
Where n is the number of samples. The prediction and observation are simulated and clinically observed 
data, respectively.
Sensitivity analysis
Sensitivity analysis was performed to determine the effect of the change of the six selected model 
parameters on the AUC following standard quinine regimen, i.e., 600 mg, every 8 hours (TID) for 7 
consecutive days. Besides, additional selected model parameters were applied for the drug combination 
model to determine their effects on the AUC3-7days of quinine following the administration of 
lopinavir/ritonavir (400/100 mg) BID for 21 consecutive days and 600 mg quinine TID administration on 
day 14 for 7 consecutive days. Six selected parameters included in the model were (i) fu, (ii) Ka, (iii) liver 
weight, (iv) Rbp, (v) fm,CYP3A4, and (vi) fm, UGT1A1. Furthermore, additional model parameters for the three 
drugs combination model were (i) Emax of ritonavir (for UGT1A1), (ii)  EC50 of ritonavir (for UGT1A1), 
(iii) Ind50 of ritonavir (for CYP3A4), (iv) Indmax of ritonavir (for CYP3A4), (v) fm,CYP3A4, (vi) fm,UGT1A1, (vii) 
fu of ritonavir, (viii) Kinact of ritonavir, and (ix) Ki of ritonavir (for CYP3A4). The effects of these model 
parameters on  AUC3-7days were evaluated by changing the value of each parameter by +20%. The positive 
sensitivity was defined as a positive correlation between the model parameters and the AUC3-7days and vice 
versa. The equation for sensitivity analysis is as follow:
Sensitivity coefficient  = %Y/%X
Where %Y is the percent change of theAUC3-7days, and %X is the percent change of model parameters.
Renal and hepatic insufficiency
The human physiological changes in hepatic insufficiency were obtained from the published article and 
applied to the model.37 The fraction of unbound drug was calculated based on the abundance of albumin in 
each class of hepatic insufficiency. Blood-to-plasma partition (Rbp) ratio was calculated based on the 
change in hematocrit.37 The renal clearance was calculated based on the estimated glomerular flow rate 
(eGFR). 
Drug combination model (DDIs model)A
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Multiple-dose of lopinavir/ritonavir (400/100 mg) given twice a day for 21 consecutive days (with co-
administration of a single dose of 600 mg quinine on day 14) were simulated at fasting state. The dose 
regimens of quinine for model simulations are shown in Table S1. The AUC Ratio (AUCR: the ratio of 
quinine AUC when administered alone and that when co-administered with lopinavir/ritonavir) was 
calculated to determine the effect of lopinavir/ritonavir on quinine pharmacokinetics. The effect of 
lopinavir on plasma protein binding displacement and the fraction of unbound quinine was estimated to be 
1.45-fold when compared with quinine alone.6  CYP3A4 inhibitory effect of quinine did not influence 
lopinavir/ritonavir clearance. The EC50 (half-maximal effective concentration) of UGT1A1 activity for 
ritonavir was assumed to be the same as rifampicin. The Emax (maximum effect at high drug concentrations) 
of UGT1A1 activity for ritonavir was assumed to be 3-fold.29
Pharmacokinetic parameters of unbound quinine co-medication with lopinavir/ritonavir were predicted in 
malaria and HIV co-infected patients, with chronic renal failure, or hepatic insufficiency, or CYP3A4 
polymorphism. AUC3-7days (mg*day/L), Cmax (mg/L), Ctrough (mg/L), volume of distribution at steady state 
(Vss: L/kg), T1/2 (h), and CL (L/h) of unbound quinine are presented as mean +(95% Confidence Interval or 
CI).
Criteria for optimal dose regimen and evaluation
The optimal dose of quinine for curative malaria treatment was determined based on the unbound of 
quinine concentration reported in the published article, i.e., unbound Ctrough and unbound AUC3-7days 
(unbound AUC3-7days > 2.18 mg*day/L, and unbound Ctrough > 0.34  mg/L).32 The toxic concentration of 
unbound quinine is > 2.18 mg/L.38,39    The effects of quinine doses on unbound AUC3-7days multiple and 
unbound Ctrough multiple were evaluated.  The unbound AUC3-7days multiple is the ratio of unbound quinine 
AUC following new regimens and the required unbound AUC based on the set criteria.  The unbound 
Ctrough multiple is the ratio of unbound quinine Ctrough of new regimens and the required unbound Ctrough 
based on the set criteria.    The dose optimization strategy flow chart is shown in Figure 2.  
RESULTS
Model verification
The AAFEs (absolute average-folding errors) (ranges) for all model validation was 1.15-fold (1.016 – 1.27) 
(Table 2).  The AAFEs (ranges) for all quinine prediction was 1.13-fold. (1.016 – 1.27) Besides, the 
AAFEs (ranges) of quinine when co-administered with lopinavir/ritonavir was 1.16-fold (1.12 -1.27). The 
AAFEs (ranges) of lopinavir as given as lopinavir/ritonavir was 1.18-fold (1.18 – 1.23). The developed 
PBPK model successfully predicted quinine disposition either when quinine was given alone or in 
combination with lopinavir/ritonavir.
Sensitivity analysisA
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Sensitivity coefficient analysis for AUC3-7days (area under the curve) of quinine (a single quinine model) 
including fu (fraction of unbound drug), Ka (absorption rate), liver weight, Rbp (blood-to-plasma partition), 
fm, CYP3A4 (fraction of CYP3A4 on drug metabolism), and fm, UGT1A1 (fraction of UGT1A1 on drug 
metabolism) were +0.18, -0.65, +0.66, +0.75, +0.82, and +0.99, respectively. In addition, sensitivity 
coefficient analysis of AUC3-7days of quinine (three drugs model), e.g., EC50 ( half-maximal effective 
concentration), Emax (maximum effect at high drug concentrations), Ind50 (concentration causing 50% 
maximal induction), Indmax (maximal fold induction), Ki3A4 (inhibitor concentration that yields half-
maximal inhibition), Kinact, CYP3A4 (inactivation rate of a given enzyme), fu, fm, CYP3A4, and fm, UGT1A1 were -
0.038, +0.62, +0.38, +0.20, +0.16, +0.13, +0.23, -0.24, and +0.41, respectively. All sensitivity coefficient 
values were < 1, indicating no significant impact of these model parameters on AUC3-7days.
Simulation of quinine plasma concentrations in malaria patients with hepatic insufficiency or 
CYP3A4 polymorphism
For the standard dose regimen of quinine, the average values of unbound AUC3-7days, unbound Cmax 
(maximal concentration), and unbound Ctrough (trough concentration) in patients with hepatic insufficiency 
and CYP3A4 polymorphism were within therapeutic ranges. In the patients with hepatic insufficiency, 
AUC3-7days, and Ctrough of unbound quinine ranged from 5.148 to 10.25 mg*day/L, and 1.63 to 2.14 
mg*day/L, respectively. In patients with Child-Pugh A and B, t1/2 values were similar to those reported in 
healthy subjects (13.63 and 14.58 h, respectively). The half-life in patients with Child-Pugh C was, 
however, increased to 18.6. The clearance in patients with Child-Pugh A and B ranged from 6.14 to 6.19 
L/h, and it decreased to 4.97 in patients with Child-Pugh C. In patients with CYP3A4 polymorphism, the 
AUC3-7days of unbound quinine ranged from 5.99 to 6.42 mg*day/L, and Ctrough of unbound quinine  ranged 
from 1.25 to 1.35 mg/L. In addition, Cmax of unbound quinine, unbound AUC3-7days, and CL (clearance) 
ranged from 1.58 to 1.75 mg/L, 2.99 to 3.34 mg*day/L, and 2.84 to 3.07 L/h, respectively.
Simulation of DDIs between quinine and HIV co-infected patients treated with lopinavir/ritonavir 
Lopinavir/ritonavir co-administration
The AUC3-7days  and Ctrough [average (95%CI)] values of unbound quinine administered as standard dose 
regimen in malaria and HIV co-infected patients treated with lopinavir/ritonavir were 2.15 (2.07 – 2.23 
mg*day/L) and 0.43 (0.41 – 0.44 mg/L), respectively. The AUCR   was approximately 0.3. Therefore, the 
suggested dose is about three times higher than the standard dose regimen i.e. 1800 mg TID.  Although this 
regimen resulted in the desired unbound drug concentrations, the average unbound AUC3-7days was 
relatively high. Therefore, the dose of quinine was decreased to 1200 mg TID to achieve comparable AUC 
to no ritonavir/lopinavir patients.  Besides, other dose regimens were simulated, i.e., 2400 mg BID and 
6000 mg once a day (QD). The pharmacokinetic parameters are summarized in Table S1. 
Quinine and lopinavir/ritonavir co-administration in patients with chronic renal failure A
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For the recommended dose regimen of quinine in malaria and HIV co-infected patients with chronic renal 
failure and treated with lopinavir/ritonavir without dialysis, the average (95%CI) values of unbound AUC3-
7days, unbound Ctrough, and AUCR were 2.55 (2.47-2.64), 0.49 (0.48-0.51) and 0.3 respectively. All 
parameters were within the reported therapeutic targets. But the unbound Ctrough concentrations were close 
to the cut-off criteria. To overcome the DDI effect, the suggested dosage was 972 mg BID (3 times higher 
than the standard dose regimen).  However, the quinine 648 mg BID regimen was considered adequate to 
provide the targeted therapeutic of unbound quinine concentrations.32 The simulated pharmacokinetic 
parameters of unbound quinine are summarized in Table S1.
Quinine and lopinavir/ritonavir co-administration in patients with hepatic insufficiency
Based on the simulation results of quinine administration alone in hepatic insufficiency, the recommended 
dosage was considered adequate to provide therapeutic unbound concentrations in malaria patients co-
infected with HIV. The average (95%CI) values of unbound AUC3-7days, unbound Ctrough, and AUCR in 
patients with mild hepatic insufficiency were 5.02 (4.83-5.20) mg*day/L, 1.06 (1.02-1.10) mg/L, and 0.67, 
respectively. The corresponding values for patients with moderate and severe hepatic insufficiency ranged 
from 7.57 to 7.7 mg*day/L, 1.58 to 1.96 mg/L, and 0.65 to 0.79, respectively.  The average unbound Cmax 
in patients with severe hepatic insufficiency was higher than toxic concentration levels. Therefore, the 
reduction of dosage administration (324 mg BID for 7 consecutive days) was simulated. The simulated 
pharmacokinetic parameters are summarized in Table S1.
Quinine and lopinavir/ritonavir co-administration in patients with CYP3A4 polymorphism
The AUC3-7days and Ctrough of unbound quinine for all CYP3A4 polymorphism ranged from 3.78 to 3.95 
mg*day/L, and 0.81 to 0.87 mg/L, respectively. The AUCR ranged from 0.42 to 0.44. Based on the AUCR 
value, the suggested dosage was 1296 mg TID for 7 consecutive days (2 times higher than the standard 
dose regimen). Furthermore, unbound plasma quinine concentrations were also simulated for the 7-day 
regimen of 972 mg TID and 1296 mg BID. The simulated pharmacokinetic parameters are summarized in 
Table S1.  The predicted unbound AUC3-7days, unbound Cmax, unbound Ctrough, Vss, CL, and t1/2 of quinine 
for optimal dose regimens in each condition are summarized in Table 3.
DISCUSSION
PBPK modeling successfully predicted quinine disposition in various clinical situations, including chronic 
renal failure without dialysis and impaired liver dysfunction (Child-Pugh A and Child-Pugh C). Some of 
the recommended dosage regimens of quinine derived from the simulations provided inadequate unbound 
plasma quinine concentrations for malaria patients when treated with lopinavir/ritonavir due to the 
metabolic DDI.  Simulated regimens of quinine, when co-administered with lopinavir/ritonavir, informed 
potential dose adjustment strategies to overcome the effects of the DDIs. Furthermore, the potential impact A
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of various patient conditions was simulated to identify suitable dosing strategies to minimize the risk of 
side effects or therapeutic failure.  
Quinine and lopinavir/ritonavir co-administration
The initially recommended 7-day regimen of 600 mg quinine TID co-administered with lopinavir/ ritonavir 
resulted in a 3-fold lower quinine exposure compared with quinine alone (Table S1). This result was in 
agreement with quinine pharmacokinetics reported in healthy Thai subjects following a single oral dose of 
600 mg quinine given in combination with lopinavir/ritonavir.5,6  The simulation of dose adjustment of 
unbound quinine suggested that 1200 mg or 1800 mg TID, or 2400 mg BID, or 6000 mg QD could 
represent suitable dosing strategies to overcome this DDI.  Nevertheless, the 1200 mg TID dose regimen is 
likely to be too low to account for the large inter-individual variability in quinine clearance and plasma 
drug concentrations.9,40
Apart from dose adjustments, the patient compliance with medication is also an important factor 
that can influence therapeutic response.41  Once-daily dose regimen has been shown to improve patient 
compliance compared with the two times daily and three times daily dose regimens.42  The simulated 
unbound exposure for the 2400 mg BID and the 6000 mg QD dose regimens were within therapeutic 
ranges. Although once-daily dose strategies could support better patient compliance, the 6000 mg QD dose 
regimen would result in an excessive number of tablets. 
Quinine and lopinavir/ritonavir interaction in patients with chronic renal failure
Acute renal failure is one of the most common complications in patients with severe malaria infection.8 
Plasma quinine concentrations in patients with acute renal failure are about 20-30% higher than non-acute 
renal failure patients.43 Nevertheless, standard quinine regimen is recommended in patients with acute renal 
failure44 as renal excretion of quinine accounts for only 20% of all elimination routes.9 However, in patients 
with chronic renal failure without hemodialysis, the recommended dose regimen of quinine was revised 
from 648 mg TID to 648 mg loading dose followed by 324 mg BID for 7 days.9 Results from the 
simulation from our study, however, suggested that the recommended dose regimen resulted in inadequate 
therapeutic unbound quinine concentrations when quinine was co-administered with lopinavir/ritonavir. 
This could be due to the shortening in elimination half-life of unbound quinine when co-administered with 
lopinavir/ritonavir as a consequence of the induction of UGT enzymes and plasma protein-binding 
displacement of lopinavir.  Results of simulation of unbound quinine concentrations when quinine was co-
administered with lopinavir/ritonavir in co-infected patients with chronic renal failure suggested inadequate 
therapeutic unbound quinine concentrations and a  higher dose may be required.  Subsequent simulation of 
the 648 mg BID regimen provided sufficient therapeutic unbound quinine concentrations (Table S1).
Quinine and lopinavir/ritonavir interaction in patients with hepatic insufficiencyA
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Approximately 80% of quinine is metabolized by hepatic drug-metabolizing enzymes.9 Even though altered 
hepatic function could have a significant impact on quinine elimination and systemic drug exposure, when 
quinine is given alone, the dose adjustment is not recommended.9  The results from the current simulation 
of unbound quinine concentrations in malaria and HIV co-infected patients with Child-Pugh C (severe 
hepatic insufficiency) hepatic impairment suggested the accumulation of unbound plasma quinine 
concentrations. This could be explained by the reduction in clearance (-24.55 %) and prolongation of 
elimination half-life (18.6 h vs 13.64 h).  Since unbound plasma quinine concentrations remain within the 
therapeutic range except for patients with severe hepatic insufficiency, dose adjustment may not be 
required.  Our simulated findings supported the recommendation by Orlando and colleges.33 Furthermore, 
results are in accordance with the product label of quinine for no requirement of dose adjustment, but with 
continued monitoring of plasma quinine concentrations.9 Babalola and colleges, on the other hand, 
recommended consideration of dose adjustment in this group of patients since quinine disposition was 
significantly altered.45   The limitation of the current study is that data from a single-instead of repeat dose 
administration was used for simulation, and therefore, therapeutic drug concentration was not achieved.  
The simulation of unbound quinine concentrations, when co-administered with lopinavir/ritonavir in 
patients with liver impairment, indicates that dose adjustment may not be required except for patients with 
severe hepatic insufficiency.  This could be explained by the decrease in quinine clearance and the 
prolongation of elimination half-life. 
Quinine and lopinavir/ritonavir interaction in patients with CYP3A4 genetic profiles
 Pharmacogenetics plays an important role in individualized therapy in modern medicine due to its 
significant impact on drug disposition, efficacy, and toxicity.46 CYP3A4/5 is the most common 
metabolizing enzymes responsible for over 50% of the clinically prescribed drug.11 With the standard 
regimen of quinine administration alone, the clearance of quinine by different CYP3A4 variants were 3 to 
5-fold lower compared to simulated patients who do not carry any CYP3A4 variants. The allele frequencies 
of the considered variants varied from 0.01 to 0.27 in Korean, Han Chinese, Japanese, African American, 
and European/American.47 The AUCR of quinine following standard regimen when co-administered with 
lopinavir/ritonavir in patients with the various variant alleles ranged from 0.43 to 0.44. The results of such 
studies suggested that the higher dose was required.  However, simulated uinbound quinine concentrations 
in patients with most impaired intrinsic clearance (CYP3A4*13) in this study suggested that the unbound 
AUC3-7days, unbound Cmax, and unbound Ctrough parameters were increased (compared to wild-type), but 
were still within therapeutic ranges.  In such a case, quinine dose adjustment may not be required. (Table 
3). There is no report on the association between ritonavir therapy and CYP3A4 polymorphism.  Besides,  
CYP3A4 mutant allele  (CYP3A4*22) which is reported to be associated with variability in lopinavir 
concentrations is different from that of quinine.48  Therefore, dose adjustment in the co-formulated 
lopinavir/ritonavir may not be required in individuals with CYP3A4 polymorphism.38A
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The developed PBPK model did not include the effect of P-glycoprotein transporter (P-gp) on the 
pharmacokinetics of both quinine, ritonavir, and lopinavir due to lack of information from in vitro studies. 
This is, however, unlikely to have a significant impact on quinine pharmacokinetics as unlike quinidine, 
quinine is a weak substrate of P-gp.49 The developed PBPK model did not include the effect of quinine 
metabolite (3-hydroxyquinine), which can inhibit CYP3A4 enzyme, leading to an increase in quinine 
plasma concentrations.  Nevertheless, considering the relatively high inhibition constant (Ki) of 3-
hydroxyquinine (3.74 mg/L)50  compared to its Cmax at steady state (1.26 mg/L)32 the clinical inhibitory 
effect is unlikely. Subsequent model development should include these factors when the information is 
available to improve model accuracy. 
In summary, the verified PBPK models successfully predicted unbound quinine disposition when 
co-administered with lopinavir/ritonavir in co-infected patients with different conditions. Suitable dose 
adjustments to overcome the DDIs were identified (1800 mg TID for 7 days).  Dose adjustment strategies 
are potentially required in patients with chronic renal failure.  However, quinine dose adjustment may not 
be required in co-infected patients with hepatic insufficiency (except for patients with severe hepatic 
insufficiency) or carrier of CYP3A4 genetic variants.    The verified PBPK models can be applied for dose 
optimization of the existing antimalarial drug when co-administered with lopinavir/ritonavir, supporting the 
design of future clinical studies.
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STUDY HIGHLIGHTS
What is the current knowledge on the topics?
Ritonavir-boosted lopinavir reduces quinine concentrations in healthy volunteers by 3-fold. The reduction 
of quinine concentrations when co-administered with lopinavir/ritonavir could lead to malaria treatment 
failure. 
What question did this study address?
What are the optimal dosages of quinine when co-administered with lopinavir/ritonavir in co-infected 
patients?
What does this study add to our knowledge?A
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Doses adjustment of quinine in co-infected patients with hepatic insufficiency (except for severe hepatic 
insufficiency) or with CYP3A4 polymorphisms is potentially not necessary. Dose adjustment is required 
for HIV co-infected with malaria patients, with renal impairment, and severe hepatic insufficiency. 
How might this change clinical pharmacology or translational science?
The co-administration of multiple drugs can cause drug-drug interactions that result in treatment failure or 
toxicity. PBPK modeling can support the design of future clinical studies for the investigation of drug-drug 
interactions
AUTHOR CONTRIBUTIONS
T.S., J.K., and K.N. wrote the manuscript; J.K. and K.N. designed the research; T.S. and M.S. performed 
research; T.S., M.S., and R.K.R.R. analysed the data.
REFERENCES
1. Holmes, C.B., Losina, E., Walensky, R.P., Yazdanpanah, Y. & Freedberg, K.A. Review of human 
immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect 
Dis  36, 652-62 (2003).
2. Kwenti, T.E. Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and 
treatment strategies. Res Rep Trop Med  9, 123-36 (2018).
3. Whitworth, J. et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia 
and clinical episodes in adults in rural Uganda: a cohort study. Lancet  356, 1051-6 (2000).
4. Kigen, G. et al. Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a 
Large Kenyan Cohort. Plos One  6, 1-7  (2011).
5. Rattanapunya, S., Cressey, T.R., Rueangweerayut, R., Tawon, Y., Kongjam, P. & Na-Bangchang, 
K. Pharmacokinetic Interactions between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults. 
Am J Trop Med Hyg  93, 1383-90 (2015).
6. Nyunt, M.M. et al. Effects of Ritonavir-Boosted Lopinavir on the Pharmacokinetics of Quinine. 
Clin Pharmacol Ther  91, 889-95 (2012).A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
7. Soyinka, J.O., Onyeji, C.O., Omoruyi, S.I., Owolabi, A.R., Sarma, P.V. & Cook, J.M. 
Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following 
concurrent administration. (vol 69, pg 262, 2010). Brit J Clin Pharmaco  69, 571- (2010).
8. da Silva, G.B., Pinto, J.R., Barros, E.J.G., Farias, G.M.N. & Daher, E.D. Kidney involvement in 
malaria: an update. Rev Inst Med Trop Sp  59, 1-6 (2017).
9. company, M.p. Qualaquin (FDA product Label). 
<https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021799s011lbl.pdf> (2013). 
Accessed 25 2019.
10. Ohtsuki, S. et al. Simultaneous Absolute Protein Quantification of Transporters, Cytochromes 
P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of 
Individual Human Liver: Comparison with mRNA Levels and Activities. Drug Metab Dispos  40, 
83-92 (2012).
11. Zanger, U.M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene 
expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeut  138, 103-41 
(2013).
12. Zhou, X.Y. et al. Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In 
Vitro. Front Pharmacol  10, 1-14  (2019).
13. Zhuang, X.M. & Lu, C. PBPK modeling and simulation in drug research and development. Acta 
Pharm Sin B  6, 430-40 (2016).
14. Vieira, M.L.T. et al. PBPK Model Describes the Effects of Comedication and Genetic 
Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways. Clin 
Pharmacol Ther  95, 550-7 (2014).
15. Siccardi, M. et al. Use of a physiologically-based pharmacokinetic model to simulate artemether 
dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol  1, 4 
(2013).
16. Richman, D.D., (ed) (2015). In Silico Simulation of Interaction Between Rifampicin and Boosted 
Darunavir. Conference on retroviruses and opportunistic infection.
17. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm Res  
10, 1093-5 (1993).
18. Dua, V.K., Sarin, R. & Prakash, A. Determination of quinine in serum, plasma, red blood cells and 
whole blood in healthy and Plasmodium falciparum malaria cases by high-performance liquid 
chromatography. J Chromatogr  614, 87-93 (1993).
19. Wanwimolruk, S. & Denton, J.R. Plasma protein binding of quinine: binding to human serum 
albumin, alpha 1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol  
44, 806-11 (1992).A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
20. Supanaranond, W. et al. Disposition of oral quinine in acute falciparum malaria. Eur J Clin 
Pharmacol  40, 49-52 (1991).
21. Zhao, X.J. & Ishizaki, T. A further interaction study of quinine with clinically important drugs by 
human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J 
Drug Metab Pharmacokinet  24, 272-8 (1999).
22. Wagner, C., Zhao, P., Arya, V., Mullick, C., Struble, K. & Au, S. Physiologically Based 
Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir 
or Lopinavir Exposure Coadministered With Ritonavir. J Clin Pharmacol  57, 1295-304 (2017).
23. Zhang, C. et al. Population pharmacokinetics of lopinavir and ritonavir in combination with 
rifampicin-based antitubercular treatment in HIV-infected children. Antivir Ther  17, 25-33 (2012).
24. Patel, M., Mandava, N., Gokulgandhi, M., Pal, D. & Mitra, A.K. Amino Acid Prodrugs: An 
Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir. Pharmaceuticals 
(Basel)  7, 433-52 (2014).
25. Ernest, C.S., Hall, S.D. & Jones, D.R. Mechanism-based inactivation of CYP3A by HIV protease 
inhibitors. J Pharmacol Exp Ther  312, 583-91 (2005).
26. Kirby, B.J., Collier, A.C., Kharasch, E.D., Whittington, D., Thummel, K.E. & Unadkat, J.D. 
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of 
cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos  39, 1070-8 (2011).
27. Xu, H., Vela, S., Shi, Y., Marroum, P. & Gao, P. In Vitro Characterization of Ritonavir Drug 
Products and Correlation to Human in Vivo Performance. Mol Pharm  14, 3801-14 (2017).
28. Koudriakova, T. et al. Metabolism of the human immunodeficiency virus protease inhibitors 
indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: 
mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos  26, 552-
61 (1998).
29. Smith, C.M., Faucette, S.R., Wang, H. & LeCluyse, E.L. Modulation of UDP-
glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers. J Biochem 
Mol Toxicol  19, 96-108 (2005).
30. Strauch, S., Dressman, J.B., Shah, V.P., Kopp, S., Polli, J.E. & Barends, D.M. Biowaiver 
monographs for immediate-release solid oral dosage forms: Quinine sulfate. J Pharm Sci-Us  101, 
499-508 (2012).
31. Mirghani, R.A., Hellgren, U., Bertilsson, L., Gustafsson, L.L. & Ericsson, O. Metabolism and 
elimination of quinine in healthy volunteers. Eur J Clin Pharmacol  59, 423-7 (2003).
32. Pukrittayakamee, S. et al. Quinine pharmacokinetic-pharmacodynamic relationships in 
uncomplicated falciparum malaria. Antimicrob Agents Ch  47, 3458-63 (2003).A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
33. Orlando, R., De Martin, S., Pegoraro, P., Quintieri, L. & Palatini, P. Irreversible CYP3A inhibition 
accompanied by plasma protein-binding displacement: a comparative analysis in subjects with 
normal and impaired liver function. Clin Pharmacol Ther  85, 319-26 (2009).
34. Peng, J.Z. et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected 
subjects with hepatic impairment. J Clin Pharmacol  46, 265-74 (2006).
35. Rimchala, P., Karbwang, J., Sukontason, K., Banmairuroi, V., Molunto, P. & Na-Bangchang, K. 
Pharmacokinetics of quinine in patients with chronic renal failure. Eur J Clin Pharmacol  49, 497-
501 (1996).
36. Saeheng, T., Na-Bangchang, K. & Karbwang, J. Utility of physiologically based pharmacokinetic 
(PBPK) modeling in oncology drug development and its accuracy: a systematic review. Eur J Clin 
Pharmacol  74, 1365-76 (2018).
37. Johnson, T.N., Boussery, K., Rowland-Yeo, K., Tucker, G.T. & Rostami-Hodjegan, A. A Semi-
Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance. Clin 
Pharmacokinet  49, 189-206 (2010).
38. Sheldon, R., Duff, H. & Koshman, M.L. Antiarrhythmic activity of quinine in humans. Circulation  
92, 2944-50 (1995).
39. Verdier, M.C., Bentue-Ferrer, D., Tribut, O. & Therap, S.F.P. Therapeutic Drug Monitoring of 
Quinine. Therapie  66, 507-16 (2011).
40. Achan, J. et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of 
malaria. Malar J  10, 144 (2011).
41. Erwin, J. & Peters, B.S. The critical relationship between compliance and the management of 
infectious diseases. Clin Microbiol Infect  4, 275-9 (1998).
42. Falagas, M.E., Karagiannis, A.K.A., Nakouti, T. & Tansarli, G.S. Compliance with Once-Daily 
versus Twice or Thrice-Daily Administration of Antibiotic Regimens: A Meta-Analysis of 
Randomized Controlled Trials. Plos One  10, 1-15 (2015).
43. Sukontason, K. et al. Plasma quinine concentrations in falciparum malaria with acute renal failure. 
Trop Med Int Health  1, 236-42 (1996).
44. Sharma, A.M., Keller, F., Boeckh, M., Heitz, J. & Borner, K. Quinine dosage in severe malaria 
with renal failure necessitating haemodialysis. Eur J Clin Pharmacol  36, 535-6 (1989).
45. Babalola Chinedum P., K.O.A., Dixon Patrick A.F., Oyewo Adefemi E. Disposition of quinine and 
its major metabolite, 3-hydroxyquinine in patients with liver diseases. Res Pharm Biotech  3, 4 
(2011).
46. Johnson, J.A. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends 
Genet  19, 660-6 (2003).A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
47. Lee, J.S. et al. Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes. Korean J 
Physiol Pharmacol  17, 479-84 (2013).
48. Olagunju, A. et al. CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir 
pharmacokinetics in HIV-positive adults. Pharmacogenet Genomics  24, 459-63 (2014).
49. Patil, A.G., D'Souza, R., Dixit, N. & Damre, A. Validation of quinidine as a probe substrate for the 
in vitro P-gp inhibition assay in Caco-2 cell monolayer. Eur J Drug Metab Pharmacokinet  36, 
115-9 (2011).
50. Zhang, H., Coville, P.F., Walker, R.J., Miners, J.O., Birkett, D.J. & Wanwimolruk, S. Evidence for 
involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol  43, 245-52 
(1997).
Figure Legends
Figure1. A schematic workflow of a single model 
Figure2. A schematic workflow of the drug interaction model
Supplementary Material
(Simulated unbound quinine exposure pharmacokinetics when quinine was administered alone and co-
administered with LPV/r (400/100 mg) in malaria HIV co-infected patients with different conditions.PDF)
Table S1. Simulated unbound quinine exposure pharmacokinetics when quinine was administered alone 
and co-administered with LPV/r in malaria HIV co-infected patients with different conditions. Set criteria 
for dose optimization are unbound AUC3-7days > 2.18 mg*day/L, unbound Cmax < 2.18 mg/L, and unbound Ctrough > 
0.34 mg/L. Data are presented as mean (95%CI) values. 
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Table 1. PBPK model input parameters for quinine, lopinavir, and ritonavir. 
Parameters Quinine Lopinavir Ritonavir 
Molecular weight 
(g/moL) 
324.42
30
 628.1
22
 721
22
 
Log P 3.44
30
 4.2
22
 3.9
22
 
pKa 8.5
30
 Neutral
22
 1.8, 2.8
22
 
Rbp (B:P) Malaria: 1.13
18 
Healthy subjects: 1.11
18
 
0.75
37
 0.58
22
 
Fraction of unbound 
drug (fu) 
Asian healthy subjects: 0.17
18
 
Caucasian healthy subjects: 
0.148
18
 
Malaria: 0.109
18 
0.01
22
 0.015
22
 
Absorption rate (Ka) 
(1/h) 
0.68
20
 0.74
22
 2.31
23
 
Solubility in fasted state 
(mg/L) 
1300
28
 - 500
27
 
Absolute bioavailability 
(Fbio) 
0.76
9 
- - 
In vivo clearance (l/h) Malaria and healthy subjects: 
12
9 
Chronic renal failure (using 
the lowest reported clearance 
in clinical trials): 5.6
9
 
- - 
Intrinsic clearance 
(CLint) (l/min/mg 
protein) 
Back-calculated from in vivo 
clearance 
- - 
CYP3A4 fm,cyp3A4=0.44 (assumed) 1.4
24
 20.14
28
 
CYP2D6 - - 0.93
28
 
UGT1A1 fm,UGT1A1=0.56 (assumed) - - 
Renal clearance (CLr) 
(ml/min/kg) 
0.305
44 
- - 
Interaction-inhibition    
CYP3A4  Ki: 17.34 (mg/L)
33
 Kinact: 6 (1/h)
25
 
Ki: 0.257 (mg/L)
25
 
Kinact: 19.8 (1/h)
29
 
Ki: 0.18 (mg/L)
29
 
Interaction induction    
CYP3A4 - - Ind50: 13.9
26
 
Indmax: 2.45 (mg/L)
26
 
UGT1A1 - - EC50: 0.281 (mg/L)
29
 
ECmax: 3
29
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Log P: logarithm of octanol-water partition coefficient; pKa: negative decadal logarithm of acid dissociation 
constant; Rbp: blood-to-plasma partition ratio; fm,cyp3A4: fraction of CYP3A4 on drug metabolism; fm,UGT1A1: 
fraction of UGT1A1 on drug metabolism; Ki: inhibitor concentration that yields half-maximal inhibition; Kinact:  
inactivation rate of a given enzyme; EC50: half-maximal effective concentration; ECmax: maximum effect at high 
drug concentrations; Ind50: concentration causing 50% maximal induction; Indmax: maximal fold induction 
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Table 2.  Model verification of quinine when administered alone and/or concomitantly with LPV/r in fasting 
state. Data are presented as mean (95% CI) values. 
Clinical study PK 
parameter 
Prediction Observation Prediction/observation 
ratios 
Quinine 
A single dose of 648 mg 
quinine QD in healthy 
volunteers
9
 
AUC0-12 
(mg*h/L) 
28.45 (27.27 
- 28.46) 
28 1.01 
Cmax (mg/L) 3.13 (3.00 - 
3.26) 
3.2 0.98 
Tmax (h) 3 (3-3) 2.8 1.07 
AAFEs   1.03 
A single dose of 648 mg 
quinine QD in malaria 
patients
9
 
AUC0-12h 
(mg*h/L) 
74.2 (71.17 
– 77.25) 
73 1.016 
Cmax (mg/L) 8.45 (8.11 - 
8.79) 
8.4 1.006 
AAFEs   1.016 
A single dose of 600 mg 
quinine QD in Caucasian 
healthy volunteer
7
 
AUC0-48days 
(mg*h/L) 
67.98 
(94.91-
71.04) 
50.06 1.357 
Cmax (mg/L) 3.07 (2.94-
3.19) 
2.79 1.099 
Clearance 
(l/h) 
7.62 (7.26-
7.99) 
9.12 0.835 
Half-life (h) 13.85 
(13.48-
14.22) 
11.15 1.24 
AAFEs   1.18 
A single dose of 600 mg 
quinine QD in Thai healthy 
volunteer
5
 
AUC0-48h 
(mg*h/L) 
135.85 
(129.46 - 
142.24) 
132.4 1.02 
AUC0-inf 
(mg*h/L) 
137.71 
(131.08-
144.34) 
136.83 1.00 
Cmax (mg/L) 7.39 (7.09-
7.70) 
7.45 0.99 
Clearance 
(l/h) 
3.80 (3.61-
4.00) 
3.34 1.13 
Vss (l/kg) 0.79 (0.78-
0.80) 
0.8 0.98 A
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Clinical study PK 
parameter 
Prediction Observation Prediction/observation 
ratios 
Half-life (h) 11.36 
(10.98-
11.74) 
10.95 10. 
Tmax (h) 3 (3-3) 2 1.36 
AAFEs   1.08 
A single dose of 600 mg 
quinine QD in Thai healthy 
volunteers
35
 
AUC0-inf 
(mg*h/L) 
60.10 
(57.47-
62.72) 
61.8 0.97 
Cmax (mg/L) 2.90 (2.78-
3.02) 
3.45 0.84 
Clearance 
(L/h) 
8.52 (8.14-
8.91) 
9.06 0.94 
Vss (l/kg) 1.97 (1.95-
2.00) 
2.11 0.938 
Half-life (h) 12.78 
(12.39-
13.18) 
9.7 1.31 
AAFEs   1.12 
A single dose of 600 mg 
quinine QD in chronic renal 
failure patients
35
 
AUC0-inf 
(mg*h/L) 
208.61 
(198.38-
218.83) 
181.5 1.149 
Cmax (mg/L) 4.55 (4.36-
4.74) 
6.17 0.73 
Clearance 
(l/h) 
3.14 (2.99 – 
3.30) 
3 1.04 
Vss (L/kg) 1.27 (1.26-
1.29) 
1.38 0.925 
Half-life (h) 22.22 
(21.44-
23.00) 
26 0.854 
AAFEs   1.18 
Multiple dose of 600 mg 
quinine administration TID for 
7 consecutive days in malaria 
patients
32
 
AUC0-2 
(mg*day/L) 
15.51 
(14.82-
16.20) 
17.4 0.89 
AUC3-7 
(mg*day/L) 
46.13 
(43.75-
48.50) 
35.37 1.30 A
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Clinical study PK 
parameter 
Prediction Observation Prediction/observation 
ratios 
AUC0-7 
(mg*day/L) 
72.21 
(69.15-
75.25) 
54.01 1.33 
Cmax (mg/L) 12.55 
(11.91-
13.19) 
11.43 1.09 
Tmax (days) 1.75 1.5 1.16 
AAFEs   1.2 
A single dose of 500 mg 
quinine QD administration in 
patient with mild hepatic 
insufficiency (Child-Pugh 
A)
33
 
Cmax (mg/L) 3.02 (2.90-
3.15) 
3.23 0.967 
Clearance 
(l/h) 
4.47 (4.26-
4.69) 
4,788 1.034 
Vss (l/kg) 1.47 (1.45-
1.50) 
1.368 1.058 
Half-life (h) 18.07 
(17.56-
18.58) 
14 1.11 
Tmax (h) 4 (4-4) 3.5 1.14 
AAFEs   1.07 
A single dose of 500 mg 
quinine QD administration in 
patient with severe hepatic 
insufficiency (Child-Pugh C)
33
 
Cmax (mg/L) 3.14 (3.02-
3.28) 
2.35 1.34 
Clearance 
(L/h) 
3.79 (3.60 – 
3.98) 
4.08 0.92 
Vss (L/kg) 1.51 (1.49-
1.53) 
2 0.756 
Half-life (h) 21.44 (20.7–
22.13) 
24.52 0.87 
Tmax (h) 4 (4 – 4) 3.5 1.14 
AAFEs   1.20 
A single dose of 648 mg 
quinine administration in 
Caucasian healthy volunteers
6
 
AUC0-inf 
(mg*h/L) 
56.09 
(53.37-
58.82) 
46.7 1.20 
Cmax (mg/L) 2.75 (2.65-
2.85) 
3.2 0.86 
Clearance 
(L/h) 
6.94 (6.59-
7.31) 
8.74 0.795 
Vss (l/kg) 1.70 (1.68- 1.99 0.855 A
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Clinical study PK 
parameter 
Prediction Observation Prediction/observation 
ratios 
1.73) 
Half-life (h) 13.65 
(13.20-
14.11) 
13.7 0.99 
Tmax (h) 3 (3-3) 3 1 
AAFEs   1.12 
A single dose of 648 mg 
quinine co-administered with 
LPV/r (400/100) in Caucasian 
healthy volunteers
7
 
AUC0-inf 
(mg*h/L) 
22.35 
(21.43-
23.28) 
24.6 0.908 
Cmax (mg/L) 1.50 (1.44-
1.57) 
1.5 1.00 
Clearance 
(L/h) 
17.27 
(16.52-
18.00) 
16.72 1.002 
Vss (L/kg) 3.09 (3.06-
3.12) 
3.43 1.032 
Half-life (h) 9.80 (9.47-
10.14) 
10.4 0.900 
AAFEs   1.05 
A single dose of 600 mg 
quinine co-administered with 
LPV/r (400/100) in Thai 
healthy subjects
5
 
AUC0-48 
(mg*h/L) 
43.63 (42.11 
- 4.15) 
57.04 0.76 
AUC0-inf 
(mg*h/L) 
46.46 
(43.83-
47.07) 
57.06 0.80 
Cmax (mg/L) 2.60 (2.51-
2.69) 
3.78 0.69 
Vss (L/kg) 1.59 (1.58 - 
1.61) 
1.65 0.97 
Clearance 
(L/h) 
10.72 
(10.37-
11.07) 
8.44 1.34 
Tmax (h) 3 (3 -3) 2 1.5 
AAFEs   1.27 
Quinine Average 
AAFEs 
  1.13 
Lopinavir 
A single dose of 600 mg AUC0-12 97.07 (89.65 93.4 1.04 A
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Clinical study PK 
parameter 
Prediction Observation Prediction/observation 
ratios 
quinine co-administered with 
LPV/r (400/100) in Caucasian 
healthy volunteers (LPV)
6
 
(mg*h/mL) - 104.49) 
Cmax (mg/L) 10.08 (9.44 - 
10.73) 
10.2 0.99 
Cmin (mg/L) 4.42 (3.87 - 
4.97) 
4.7 0.94 
Half-life (h) 15.27 (14.61 
- 15.93) 
9.9 1.54 
AAFEs   1.14 
Multiple dose of LPV/r 
(400/100 mg) BID for 14 
consecutive days (LPV) in 
patients with mild hepatic 
impairment
34
 
AUC0-12 
(mg*h/L) 
98.83 (92.95 
- 104.71) 
109.5 0.90 
Cmax (mg/L) 10.06 (9.52 - 
10.60) 
12.22 0.82 
Ctrough 
(mg/L) 
5.35 (4.94 - 
5.76) 
8.71 0.61 
Half-life (h) 9.10 (8.74 - 
9.45) 
9.6 0.95 
AAFEs   1.23 
Multiple dose of LPV/r 
(400/100 mg) BID for 14 
consecutive days (LPV) in 
patients with moderate hepatic 
impairment
34
 
AUC0-12 
(mg*h/L) 
123.37 
(115.41 - 
131.32) 
91.5 1.35 
Cmax (mg/L) 11.98 (11.28 
- 12.67) 
10.48 1.14 
Ctrough 
(mg/L) 
7.71 (7.11 - 
8.30) 
7.81 0.99 
Half-life (h) 9.92 (9.46 - 
10.39) 
12.5 0.79 
AAFEs   1.18 
Lopinavir Average 
AAFEs 
  1.18 
All cases Average 
AAFEs 
  1.15 
AAFEs: Average-folding errors; RMSE: root mean square errors; AUC: Area Under the curve; Cmax: maximum 
concentration; Ctrough: trough concentration 
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Table 3. Pharmacokinetic parameters of unbound quinine from simulated optimal dose regimens of quinine when co-administered with LPV/r (400/100 mg) BID in malaria 
and HIV co-infected patients. Set criteria for dose optimization are unbound AUC3-7days > 2.18 mg*day/L, unbound Cmax < 2.18 mg/L, and unbound Ctrough > 0.34 mg/L. Data 
are presented as mean (95% CI) values 
Number Conditions Regimen Unbound 
AUC3-7days 
(mg*day/L) 
(95%CI) 
Unbound 
Cmax (mg /L) 
(95%CI) 
Unbound 
Ctrough (mg/L) 
(95%CI) 
Vss (L/kg) 
(95%CI) 
Clearance (L/h) 
(95%CI) 
Half-life (h) 
(95%CI) 
1 Malaria co-infection with 
HIVs 
1800 mg TID  5.27  
(5.09-5.46) 
1.45 
(1.40-1.50) 
1.07  
(1.04-1.12) 
2.75  
(2.72-2.79) 
16.72  
(16.12-17.34) 
8.70  
(8.43-8.98) 
2 Malaria co-infection with 
HIVs with chronic renal 
failure 
648 mg BID  4.71 
(4.52-4.87) 
1.12 
(1.07-1.16) 
0.88 
(0.85-0.91) 
3.37  
(3.34 - 3.4) 
10.16  
(9.75-10.58) 
17.95  
(17.39-18.50) 
3 Malaria co-infection with 
HIVs with mild hepatic 
insufficiency 
648 mg TID  5.05 
(4.85-5.25) 
1.34  
(1.29-1.40) 
1.07 
(1.03-1.12) 
2.75  
(2.71 - 2.79) 
7.43  
(7.15-7.71) 
7.43  
(7.15-7.71) 
Malaria co-infection with 
HIVs with moderate hepatic 
insufficiency 
648 mg TID  7.71  
(7.45-7.95) 
2.06 
(2.00-2.13) 
1.62 
(1.56-1.71) 
2.82  
(2.79 - 2.85) 
5.56  
(5.39-5.74) 
27.03  
(26.45-27.61) 
Malaria co-infection with 
HIVs with severe hepatic 
insufficiency 
324 mg BID  5.56 
(5.35-5.79) 
1.44 
(1.39-1.50) 
1.00 
(0.97-1.05) 
2.70  
(2.67-2.74) 
5.64  
(5.50 – 5.83) 
28.32  
(27.71 – 29.02) 
4 Malaria co-infection with 
HIVs with CYP3A4*3 
 
648 mg TID  3.38 
(3.74-4.02) 
1.05 
(1.02-1.09) 
0.84 
(0.82-0.88) 
2.74 
(2.71-2.78) 
5.52 
(5.30-5.74) 
26.46 
(25.70-27.23) A
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Number Conditions Regimen Unbound 
AUC3-7days 
(mg*day/L) 
(95%CI) 
Unbound 
Cmax (mg /L) 
(95%CI) 
Unbound 
Ctrough (mg/L) 
(95%CI) 
Vss (L/kg) 
(95%CI) 
Clearance (L/h) 
(95%CI) 
Half-life (h) 
(95%CI) 
Malaria co-infection with 
HIVs with CYP3A4*13 
648 mg TID  3.95  
(3.79-4.09) 
1.08 
(1.04-1.12) 
0.87 
(0.84-0.90) 
2.74 
(2.71-2.78) 
4.39 
(4.22-4.57) 
33.47 
(32.51-34.44) 
Malaria co-infection with 
HIVs with CYP3A4*18 
648 mg TID  3.90 
(3.76-4.04) 
1.06 
(1.03-1.10) 
0.85 
(0.82-0.88) 
2.75 
(2.72-2.79) 
5.24 
(5.02-5.46) 
27.81  
(26.95-28.66) 
Malaria co-infection with 
HIVs with CYP3A4*19 
648 mg TID  3.78 
(3.64-3.92) 
1.02 
(0.98-1.06) 
0.82 
(0.78-0.85) 
2.74 
(2.71-2.78) 
7.03  
(6.71-7.36) 
20.93 
(20.17-21.71) 
Unbound AUC3-7: unbound plasma concentration from day 3 to day 7 (mg*day/L); unbound Cmax: unbound maximum concentration (mg/L); unbound Ctrough: unbound trough 
concentration (mg/L) LPV: lopinavir; r: ritonavir; TID: three times a day; BID: Bis In Die; QD: once a day. Vss: volume of distribution at steady state (L/kg).  
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